基于生长抑素受体的颅内肿瘤 PET/CT：68Ga-DOTA 肽的潜在应用领域？
Somatostatin receptor-based PET/CT of intracranial tumors: a potential area of application for 68 Ga-DOTA peptides?
机构信息
1 All authors: Department of Nuclear Medicine, All India Institute of Medical Sciences, E-81, Ansari Nagar (East), AIIMS Campus, New Delhi 110029, India.
出版信息
AJR Am J Roentgenol. 2013 Dec;201(6):1340-7. doi: 10.2214/AJR.13.10987.
OBJECTIVE
Similar to neuroendocrine tumors (NETs) at other sites, a wide array of intracranial tumors also express somatostatin receptors (SSTRs). This expression can be exploited for both imaging and therapy. The introduction of (68)Ga-labeled tetraazacyclododecanetetraacetic acid (DOTA)-peptide PET/CT has given new dimension to SSTR-based imaging because of its improved sensitivity and excellent spatial resolution.
CONCLUSION
However, in contrast to gastropancreatic and bronchopulmonary NETs, limited literature is available regarding the use of (68)Ga-DOTA-peptide PET/CT in intracranial tumors. Here, we briefly review the available literature and highlight the potential role that (68)Ga-DOTA-peptide PET/CT can play in the management of intracranial tumors.
目的
与其他部位的神经内分泌肿瘤 (NETs) 类似，颅内肿瘤也广泛表达生长抑素受体 (SSTRs)。这种表达可用于成像和治疗。由于 (68)Ga 标记的四氮杂环十二烷四乙酸 (DOTA)-肽 PET/CT 的引入，其敏感性和出色的空间分辨率得到了提高，基于 SSTR 的成像有了新的维度。
结论
然而，与胃胰 NETs 和肺 NETs 相比，关于 (68)Ga-DOTA-肽 PET/CT 在颅内肿瘤中的应用，相关文献有限。在这里，我们简要回顾了现有文献，并强调了 (68)Ga-DOTA-肽 PET/CT 在颅内肿瘤管理中可能发挥的作用。
Zotero 插件